CBP-501

• Description :

  CBP-501, a cell-permeable calmodulin-binding peptide and a G2-abrogating drug candidate, inhibits the activity of multiple Ser216-specific kinases, such as MAPKAP-K2, C-Tak1, CHK1 and CHK2, with IC50 values of 0.9 μM, 1.4 μM 3.4 μM and 6.5 μM, respectively. CBP-501 is used for various types of cancer[1][2].

• UNSPSC :

  12352209

• Target :

  Calmodulin; Checkpoint Kinase (Chk) ; MAP3K; MAPKAPK2 (MK2)

• Type :

  Peptides

• Related Pathways :

  Cell Cycle/DNA Damage; MAPK/ERK Pathway; Membrane Transporter/Ion Channel

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/cbp-501.html

• Purity :

  99.75

• Smiles :

  N=C(N)NCCC[C@H](C(O)=O)NC([C@@H](CCCNC(N)=N)NC([C@@H](CCC(N)=O)NC([C@@H](CCCNC(N)=N)NC([C@@H](CCCNC(N)=N)NC([C@@H](CCCNC(N)=N)NC([C@@H](CC1CCCCC1)NC([C@@H](CC2=C(F)C(F)=C(F)C(F)=C2F)NC([C@@H](CO)NC([C@@H](CC3=CNC4=CC=CC=C34)NC([C@@H](CO)NC([C@@H](CC5=CC=C(C(C6=CC=CC=C6)=O)C=C5)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O

• Molecular Formula :

  C86H122F5N29O17

• Molecular Weight :

  1929.06

• References & Citations :

  [1]Enzler T, et al. A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma. Eur J Cancer. 2024 Apr;201:113950.|[2]Shi-Ken Sha, et al. Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint. Mol Cancer Ther. 2007 Jan;6 (1) :147-53.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category :

  Peptides

• Clinical Information :

  Phase 2

• Isoform :

  Chk1; Chk2; MAP3K7/TAK1

• CAS Number :

  [565434-85-7]